South Korea

SillaJen Biotherapeutics is planning to go public with an eye to raise W205bn ($179.4m), according to a termsheet seen by GlobalCapital Asia.

South Korea is in the midst of a serious political scandal that could threaten the president, but it seems to have had little impact on the IPOs of Clio Cosmetics Co and Doosan Bobcat.

South Korea’s Clio Cosmetics Co has raised W184.5bn ($161.9m) from a successful IPO, pulling off the deal even as controversy around the country’s president shakes market confidence, causing some local investors to stay away.

Japan’s Nippon Steel & Sumitomo Metal Corp has raised W177bn ($154.6m) from the sale of some of its shares in Posco — the third sell-down of its stake in the South Korean steelmaker this year.

Samsung BioLogics Co has priced its IPO at the top on the back of a surge in chunky orders, raising W2.25tr ($2.0bn) in South Korea's largest float since 2010.

South Korea’s KCC Corp is planning an up to W800bn ($706m) bond exchangeable into shares of Samsung C&T Corp, according to sources close to the matter.

South Korea's Hotel Lotte Co is planning to return to equity capital markets in the near future with another IPO attempt, chairman Shin Dong-bin said in a press briefing on Tuesday.

New Silkroad Culturaltainment plans to raise HK$1.5bn ($193.3m) from a proposed open offer of shares, according to a filing with the Hong Kong Stock Exchange.

ZTO Express and Samsung BioLogics are seeing bumper responses for their jumbo IPOs in the US and South Korea respectively, as bankers expect their bookbuilds to gain even more momentum.

Doosan Bobcat and its IPO advisers were left red-faced after the company was forced to pull its W2.4tr ($2.2bn) float in South Korea last week. The deal is making a quick comeback and the leads have done what they can to turn the situation around. But the incident serves as an object lesson in how not to do an IPO.

Korea National Oil Corp priced a dual-tranche offering on Monday, selling a 10 year portion at a tighter spread than a five year, according to bankers.

South Korea’s Samsung BioLogics gathered enough orders from investors to cover its W2.25tr ($2.0bn) IPO after the very first day of bookbuilding.